# Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE)

> **NCT04515394** · PHASE2 · TERMINATED · sponsor: **EMD Serono Research & Development Institute, Inc.** · enrollment: 3 (actual)

## Conditions studied

- Colorectal Neoplasms

## Interventions

- **DRUG:** Tepotinib
- **BIOLOGICAL:** Cetuximab

## Key facts

- **NCT ID:** NCT04515394
- **Lead sponsor:** EMD Serono Research & Development Institute, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-01-28
- **Primary completion:** 2022-03-14
- **Final completion:** 2022-03-31
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** The study was terminated early due to operational challenges identifying suitable participants for screening in the study.
- **Last updated:** 2022-12-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04515394

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04515394, "Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04515394. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*